Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27260463 | 0.98 | LMNA (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL22305025 | 0.98 | LMNA (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL23920461 | 0.86 | LMNA (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL22641327 | 0.82 | CES2 (0.39) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL19447747 | 0.81 | LMNA (0.40) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL17882175 | 0.80 | LMNA (0.43) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL27335754 | 0.79 | LMNA (0.39) | LMNA | |
| SCHEMBL19981877 | 0.79 | MEN1 (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL3964300 | 0.78 | LMNA (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL12251777 | 0.77 | LMNA (0.46) | LMNAMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | LMNA 3474/4885MEN1 1395/4885CYP3A4 2815/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | LMNA 3480/4885MEN1 1103/4885CYP3A4 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.